Where does Cidara Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cidara Therapeutics, Inc. ranks #18,489 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cidara Therapeutics, Inc. hold?

Cidara Therapeutics, Inc. holds 15 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is Cidara Therapeutics, Inc.'s Innovation Score?

Cidara Therapeutics, Inc. has an Innovation Score of 39.5 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cidara Therapeutics, Inc. focus on?

Cidara Therapeutics, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 15 patents, ranking #1,511 of 7,163 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Cidara Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Cidara Therapeutics, Inc.'s recent grant velocity is +80% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Cidara Therapeutics, Inc.'s patents?

Cidara Therapeutics, Inc.'s patents average 17.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cidara Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cidara Therapeutics, Inc.

USPTO PatentsView assignee record - 15 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cidara ranks #18,489 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 7 technology areas.

#18,489
of 49,997 US assignees by volume: Top 38%
by Innovation Score (39.5/100): 17.7
avg claims per patent: +80%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18489 · US Corporation #18,489 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,489/49,997
PHOTO-FINISH Chant Sincere
CPC-NARROW A61K · 7 areas
INNOV-THIN 39.5/100
CLAIMS-RICH 17.7 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +80% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Chant Sincere Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cidara’s 39.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (24%) Velocity 10.0 pts (25%) Breadth 9.4 pts (24%) Claim depth 10.6 pts (27%)

Qualcomm Incorporated · highest

85
Cidara Therapeutics · this assignee

40
3D Lighting… · lowest

7

What this shows Cidara's Innovation Score is 39.5/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cidara?

Each dot is one of Cidara’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cidara’s own 17.7 claims/patent is ABOVE the 12.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cidara vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cidara's grants concentrate

Cidara Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2015. By volume, Cidara sits between Chant Sincere Co., Ltd. and Codex Corporation.

Cidara's three-year grant acceleration

Cidara Therapeutics, Inc. shows 6 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Chant Sincere

15
Charlotte's Web

15
China Triumph Int…

15
Chloe S

15
Civic

15
Civitas Therapeut…

15
Clearplay

15
Codex

15
Cidara Therapeuti… ◀

15

What this shows Cidara holds 15 patents at rank #18,496, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cidara

By rank, the assignees closest to #18,496 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Cidara's primary technology class.

Cidara's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 38% higher than 62% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cidara Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	6.7%
2016	1	6.7%
2017	1	6.7%
2018	1	6.7%
2019	1	6.7%
2020	2	13.3%
2021	1	6.7%
2022	2	13.3%
2023	4	26.7%
2025partial year	1	6.7%

Which technologies does Cidara Therapeutics, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 15

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

C07K - Peptides 6

C07D - Heterocyclic Compounds 4

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cidara Therapeutics, Inc.'s patent record in context - here's where to go next.

Cidara Therapeutics, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #18,489 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cidara Therapeutics, Inc. against Chant Sincere Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.